Related Experiment Video
Updated: May 15, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
Long-Term Performance of Two Systems for Automated Insulin Delivery in Adults With Type 1 Diabetes: An Observational
Sanne Fisker1, Mia Christensen2, Ermina Bach1,3
1Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Endocrinology, Diabetes & Metabolism
|April 8, 2025
Summary
The Tandem Control IQ (CIQ) system showed higher glucose sensor wear but lower time in range (TIR) and tighter range (TITR) compared to the MiniMed 780G (MM780G) system.
Area of Science:
- Endocrinology
- Diabetes Technology
- Metabolic Health
Background:
- Automated insulin delivery (AID) systems aim to improve glycemic control in type 1 diabetes.
- Comparing different AID systems is crucial for optimizing patient outcomes.
Purpose of the Study:
- To compare the glycemic outcomes of the Tandem Control IQ (CIQ) and MiniMed 780G (MM780G) automated insulin delivery systems.
Main Methods:
- An observational study evaluated 60 days of glycemic data from 139 individuals with type 1 diabetes.
- Participants used either the CIQ (n=79) or MM780G (n=60) system with ≥85% active glucose sensor time.
Main Results:
- The CIQ system demonstrated higher active glucose sensor time (98.5% vs 96.5%, p<0.001).
- However, CIQ users had lower time in range (TIR) (68.9% vs 73.7%, p=0.02) and time in tight range (TITR) (43.0% vs 48.4%, p=0.01) compared to MM780G users.
- CIQ also showed a higher time with rapid glucose rate of change (9.4% vs 7.4%, p<0.001).
Conclusions:
- The CIQ system achieved higher glucose sensor utilization but resulted in reduced TIR and TITR.
- The MM780G system demonstrated superior glycemic control within target ranges.
- Differences in TIR and TITR remained significant after controlling for baseline variables.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
129
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
129
01:27Insulin Formulations: Types and Delivery
143
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
143
01:22Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
01:15Diabetes: Management and Pharmacotherapy
214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
01:15Diabetes: Symptoms, Diagnosis, and Complications
487
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
487
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K